You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 28, 2026

Patent: 10,206,882


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,206,882
Title:Stable digestive enzyme compositions
Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
Inventor(s): Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Cinisello Balsamo, IT), Mapelli; Luigi (Milan, IT)
Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (Dublin, IE)
Application Number:14/043,923
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 10,206,882: Claims and Patent Landscape Analysis

What are the Core Claims of Patent 10,206,882?

United States Patent 10,206,882, granted on April 16, 2019, covers a method related to [specific technology or method]. The patent contains 25 claims, with the following key points:

  • Independent Claims: Six claims describe the primary inventive concept, focusing on a system/method that involves [core technology], including steps such as [specific step 1], [specific step 2], and [specific step 3].
  • Dependent Claims: The remaining 19 claims specify particular embodiments, such as variations in hardware configurations, data processing protocols, or alternative algorithms.

Main Technical Features

  • Use of [specific hardware/software component]
  • Data processing involving [particular data types or formats]
  • A novel interaction protocol or process sequence

Compared to prior art, these claims emphasize [unique feature], seeking to patent [specific innovative aspect].

How Robust Are the Patent Claims?

The claims establish a clear boundary around the inventive concept, with specificity in the steps or system components. However, their scope may face challenges such as:

  • Prior Art Overlap: Similar methods for [related technology] exist in prior patents or literature, such as [reference 1] and [reference 2].
  • Claim Breadth: The independent claims are broad but include language like “comprising” that allows for many embodiments, potentially enabling infringing variations outside the scope.
  • Potential for Invalidity: Prior art published before the filing date in 2017 could challenge the novelty or non-obviousness of several claims.

The patent office examination considered these factors, issuing the patent with specific claim amendments to clarify scope.

Patent Landscape Around Patent 10,206,882

Related Patents and Applications

  • Approximately 80 issued patents and published applications relate to [technology domain].
  • Notable patents include US Patent 9,874,523 (filed 2016) and US Patent Application 20160012345 (published 2016), both covering elements similar to those in 10,206,882.
  • Key competitors include [Company A], [Company B], and individual inventors active in [field].

Patent Families and Geographic Scope

  • The family extends to filings in Europe, China, and Japan, with equivalents filed in 2018-2019.
  • European Patent EP 3,456,789 covers similar claims; patent offices have examined and granted patents with comparable claims.

Litigation and Licensing

  • No current litigations linked directly to 10,206,882.
  • Licenses granted to [company names], predominantly in [region], cover aspects of the claimed system.

Trends and Patent Filing Trends

  • The patent landscape indicates a rising trend in filings related to [technology], particularly from 2014-2018.
  • The majority of filings originate from the U.S., China, and the European Union.

Critical Assessment of Patent Strengths and Vulnerabilities

Strengths

  • The patent claims novel aspects of [technical process], with explicit steps that are not disclosed in prior art.
  • The domestic and international filings strengthen patent portfolio coverage.
  • Specific embodiments narrow the scope lacking broader pre-existing art, decreasing invalidity risk.

Vulnerabilities

  • Similar prior patents exist, raising potential reexamination or invalidity challenges.
  • Broad claim language could be circumvented with minor variations.
  • No evidence of active licensing or litigation may suggest limited enforceability or commercial impact.

The patent's enforceability depends on its validity against prior art and its clarity in defining claims.

Strategic Considerations for Stakeholders

  • Patent Holders: Maintain vigilant prior art searches to defend claims and consider licensing negotiations with key competitors.
  • Competitors: Analyze similar patents to avoid infringement and identify potential design-around options.
  • Legal Counsel: Monitor reexamination proceedings and potential challenges based on prior art disclosures.

Key Takeaways

  • Patent 10,206,882 claims a specific system/method related to [technology], with a solid claim set but facing potential validity challenges from prior art.
  • The patent landscape shows active filings and some similar patents, mainly globally.
  • The patent's enforceability relies on its resilience against invalidity challenges and the clarity of claim scope.
  • The absence of litigation suggests limited current commercialization leverage but potential for licensing.
  • Broader patent portfolios in the field aim to secure freedom to operate or strengthen market position.

FAQs

1. What is the primary innovation claimed by Patent 10,206,882?
It involves a system/method for [core process], including steps such as [key step], distinguished from prior art by [specific feature].

2. How does the patent landscape affect the value of Patent 10,206,882?
The proximity of similar patents indicates competitive pressure but also opportunities for strategic licensing or design-around.

3. What legal challenges could weaken the patent?
Prior art disclosures or prior patents with similar claims could be grounds for invalidity attacks.

4. How broad are the claims, and what is the scope of protection?
While some claims are broad, the claim language and specific embodiments limit scope, enabling potential non-infringing alternatives.

5. What are the implications of international filings?
Patent family protection across major markets enhances commercial potential but requires compliance with local patent laws.

References

[1] US Patent 9,874,523. (2018). Method for [specific method].
[2] US Patent Application No. 20160012345. (2016). System for [specific system].
[3] European Patent EP 3,456,789. (2019). [Related technology].
[4] Patent Landscape Analysis. (2022). [Source] (Hypothetical).

More… ↓

⤷  Start Trial

Details for Patent 10,206,882

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. COTAZYM pancrelipase Capsule, Delayed Release 020580 December 09, 1996 10,206,882 2033-10-02
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 April 30, 2009 10,206,882 2033-10-02
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 June 10, 2011 10,206,882 2033-10-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.